Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
XXIV is a science-driven skincare and longevity company focused on addressing the root causes of skin aging through mitochondrial health. The company's flagship brand, twentyfour skincare, utilizes patented sustained-release technologies to deliver active ingredients continuously over a 24-hour period. Its core products, StepZero and HYDRÍQ, incorporate the Z-pod delivery system and the AI-discovered active ingredient Y100, which is derived from the amla tree and specifically targets mitochondrial function. XXIV aims to redefine the anti-aging market by moving beyond superficial treatments to cellular-level rejuvenation with clinically proven efficacy that significantly outperforms traditional ingredients like retinol.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on XXIV.